Benitec Biopharma

BNTC

Market cap $412M

Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its full year ended June 30, 2025.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.